|Bid||108.20 x 800|
|Ask||114.00 x 900|
|Day's Range||109.81 - 111.26|
|52 Week Range||93.25 - 130.94|
|Beta (5Y Monthly)||0.67|
|PE Ratio (TTM)||28.12|
|Earnings Date||Apr 18, 2023 - Apr 24, 2023|
|Forward Dividend & Yield||2.04 (1.86%)|
|Ex-Dividend Date||Jan 12, 2023|
|1y Target Est||122.83|
Subscribe to Yahoo Finance Plus to view Fair Value for ABT
It's that time of year when Wall Street analysts start adjusting their predictions, and one dividend-paying stock, in particular, is getting a lot of positive attention. Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Since then, Sanford C. Bernstein, Raymond James, Stifel Nicolaus, and Barclays have all raised their price targets on the healthcare conglomerate.
Abbott Laboratories ( NYSE:ABT ) Full Year 2022 Results Key Financial Results Revenue: US$43.7b (up 1.3% from FY 2021...
Abbott Laboratories (NYSE:ABT) Q4 2022 Earnings Call Transcript January 25, 2023 Operator: Good morning and thank you for standing by. Welcome to Abbott’s Fourth Quarter 2022 Earnings Conference Call. This call is being recorded by Abbott. With the exception of any participants’ questions asked during the question-and-answer session, the entire call, including the question-and-answer session, […]